Deciphering the role of posttranslational modifications on α-synuclein aggregation and toxicity
Objective: The precise contribution of alpha-synuclein (ASYN) to neuronal dysfunction and death is still unclear. There is intense debate on the nature of the toxic…Neuromelamin-MRI in patients with Pure Autonomic Failure
Objective: To assess the utility of neuromelanin-MRI (NM-MRI) methods in a prodromal alpha-synuclein disorder, Pure Autonomic Failure (PAF). Background: PAF is a peripheral alpha-synucleinopathy (AS)…Incidence, prevalence and clinical features of sleep disorders in alphasynucleinopthies: A cohort study
Objective: Analyze the sleep disorders incidence, prevelence an clinical features depending on the time of evolution, depending on the type of alpha-synuclein, and the subtype…Free-living gait in REM sleep behaviour disorder: Measures of prodromal Parkinson’s disease?
Objective: The aim of this study was to investigate if free-living gait monitoring can discriminate individuals with REM sleep behaviour disorder (RBD) from controls. Background:…Early synaptic loss and synaptic instability in a mouse model of prodromal Parkinson’s disease
Objective: In order to elucidate very early pathologis of Parkinson’s disease (PD), we focused on synaptic pathologies in a newly developed mouse model of prodromal…A founder French-Canadian GBA mutation, p.W378G, as a cause for synucleinopathies and Gaucher disease
Objective: To examine and characterize founder GBA mutations in the French-Canadian (FC) population Background: GBA mutations are the most common genetic risk factors for Parkinson’s…Temporal evolution of biomarkers from healthy ageing, isolated REM sleep behavior to early Parkinson’s disease
Objective: To study the temporal evolution of biomarkers of various modalities in healthy ageing controls (HC), the prodromal condition of isolated REM sleep behavior disorder…GBA haploinsufficiency accelerated alpha synuclein pathology with altered lipid metabolism in a premotor model of Parkinson’s disease
Objective: To make Parkinson’s disease (PD) mice model and investigate the mechanism how glucocerebrosidase (gba) heterozygous mutations contribute to asyn pathology and development of PD.…Natural occurring antibodies reduce aggregation of α-synuclein
Objective: We tested naturally occurring antibodies (nAbs) against α-synuclein both in vitro as well as in HEK293T cells to determine binding, cell viability and capacity…Development of anti-amyloid drugs for Parkinson’s disease by combination screening of high-throughput in vitro assay and phenotype-based C. elegans system
Objective: To establish a new combination screening system consisted of high-throughput in vitro assay with phenotype-based in vivo assay and to develop anti-amyloid drugs truly…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 17
- Next Page »